<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><label>Table 2.</label><caption><title>Geometric means of viable tumor residues after treatment of cTACE or TILA-TACE in the nonrandomized cohort of 57 patients.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th colspan="2" valign="top">Geometric mean (95% CI)</th><th valign="top"/></tr><tr><th valign="top"/><th valign="top">cTACE (n=27)</th><th valign="top">TILA-TACE (n=30)</th><th valign="top">p value</th></tr></thead><tbody><tr><td valign="top">Crude VTR</td><td valign="top">45.1% (30.3%&#8211;67.0%)</td><td valign="top">7.1% (4.4%&#8211;11.5%)</td><td valign="top">&lt;0.0001</td></tr><tr><td valign="top">Multivariable adjusted VTR*</td><td valign="top">45.6% (28.9%&#8211;72.0%)</td><td valign="top">7.1% (4.6%&#8211;10.9%)</td><td valign="top">&lt;0.0001</td></tr></tbody></table><table-wrap-foot><fn><p>VTR: viable tumor residues;</p><p>cTACE: transarterial chemoembolization;</p></fn><fn><p>TILA-TACE: targeting-intratumoral-lactic-acidosis TACE;</p><p>*Adjusted for viable tumor volume prior to treatment and macrovascular invasion using the general linear regression. No appreciable alterations in results were found after adjustment for other covariates such as age, BCLC tumor stage, extra-hepatic metastasis, HBV DNA copy numbers, and tumor multifocality.</p></fn></table-wrap-foot></table-wrap>